PMID- 26112902
OWN - NLM
STAT- MEDLINE
DCOM- 20160706
LR  - 20210426
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Print)
IS  - 0300-8177 (Linking)
VI  - 408
IP  - 1-2
DP  - 2015 Oct
TI  - The combined treatment with novel platinum(II) complex and anti-MUC1 increases 
      apoptotic response in MDA-MB-231 breast cancer cells.
PG  - 103-13
LID - 10.1007/s11010-015-2486-z [doi]
AB  - New strategy of cancer's targeting treatment is combining monoclonal antibodies 
      with chemotherapeutic agents. An important goal of targeted therapy appears to be 
      a transmembrane glycoprotein type I-mucin 1 (MUC1), which is overexpressed in 
      tumors of epithelial origin, especially in breast cancer. The goal of the study 
      was to check the effect of monoclonal antibody against MUC1 with novel 
      platinum(II) complex (Pt12) on selected aspects of apoptosis in human MDA-MB-231 
      breast cancer cells. The number of apoptotic and necrotic cells was measured 
      using annexin V binding assay. The decrease of mitochondrial membrane potential 
      (MMP) and DNA fragmentation was analyzed. Finally, the influence of novel 
      platinum(II) complex (Pt12) used with anti-MUC1 on the concentration of selected 
      markers of apoptosis such as Bax, caspase-8, -9, and caspase-3 was performed 
      using ELISA. The results from combined treatment were compared with those 
      obtained using monotherapy. In our study, we proved that anti-MUC1 used in 
      combination with Pt12 strongly induced apoptosis in MDA-MB-231 breast cancer cell 
      line. The effect was stronger than treatment with Pt12, cisplatin, anti-MUC1, and 
      anti-MUC1 used with cisplatin. We also observed the highest decrease of MMP and 
      the strongest DNA fragmentation after such a combined treatment. The results 
      obtained from ELISA showed increased concentration of Bax, caspases-8, -9, -3 
      compared to monotherapy. Our study proved that Pt12 together with anti-MUC1 
      strongly induced apoptosis in estrogen-negative breast cancer cell line 
      (MDA-MB-231). The apoptosis may go through extrinsic pathway associated with 
      caspase-8 as well as intrinsic pathway connected with caspase-9.
FAU - Gornowicz, Agnieszka
AU  - Gornowicz A
AD  - Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 
      15-089, Bialystok, Poland. agnieszka.gornowicz@umb.edu.pl.
FAU - Bielawska, Anna
AU  - Bielawska A
AD  - Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 
      15-089, Bialystok, Poland.
FAU - Czarnomysy, Robert
AU  - Czarnomysy R
AD  - Department of Synthesis and Technology of Drugs, Medical University of Bialystok, 
      Kilinskiego 1, 15-089, Bialystok, Poland.
FAU - Gabryel-Porowska, Halina
AU  - Gabryel-Porowska H
AD  - Deparment of Medical Chemistry, Medical University of Bialystok, Kilinskiego 1, 
      15-089, Bialystok, Poland.
FAU - Muszynska, Anna
AU  - Muszynska A
AD  - Department of Synthesis and Technology of Drugs, Medical University of Bialystok, 
      Kilinskiego 1, 15-089, Bialystok, Poland.
FAU - Bielawski, Krzysztof
AU  - Bielawski K
AD  - Department of Synthesis and Technology of Drugs, Medical University of Bialystok, 
      Kilinskiego 1, 15-089, Bialystok, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150627
PL  - Netherlands
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 0 (Organoplatinum Compounds)
SB  - IM
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Apoptosis
MH  - Breast Neoplasms/*drug therapy/immunology
MH  - Cell Line, Tumor
MH  - Combined Modality Therapy/*methods
MH  - DNA Fragmentation/drug effects
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - Mucin-1/*immunology
MH  - Organoplatinum Compounds/*pharmacology
PMC - PMC4768227
OTO - NOTNLM
OT  - Anti-MUC1
OT  - Anticancer drugs
OT  - Apoptotic markers
OT  - Platinum complexes
OT  - Targeted therapy
EDAT- 2015/06/27 06:00
MHDA- 2016/07/07 06:00
PMCR- 2015/06/27
CRDT- 2015/06/27 06:00
PHST- 2015/01/20 00:00 [received]
PHST- 2015/06/18 00:00 [accepted]
PHST- 2015/06/27 06:00 [entrez]
PHST- 2015/06/27 06:00 [pubmed]
PHST- 2016/07/07 06:00 [medline]
PHST- 2015/06/27 00:00 [pmc-release]
AID - 10.1007/s11010-015-2486-z [pii]
AID - 2486 [pii]
AID - 10.1007/s11010-015-2486-z [doi]
PST - ppublish
SO  - Mol Cell Biochem. 2015 Oct;408(1-2):103-13. doi: 10.1007/s11010-015-2486-z. Epub 
      2015 Jun 27.